Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 14, 2021

Prior Pertuzumab Treatment Does Not Impact Safety or Efficacy of T-DM1 in HER2+ Metastatic Breast Cancer

BMC Cancer


Additional Info

BMC Cancer
Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
BMC Cancer 2021 Oct 27;21(1)1150, LS Al Rabadi, MM Cook, AJ Kaempf, MM Saraceni, MA Savin, ZI Mitri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading